

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Lutetium Lu 177 Dotatate. [Updated 2020 Aug 17].


Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



Lutetium Lu 177 Dotatate

Revised: August 17, 2020.

CASRN: 437608-50-9



Drug Levels and Effects

Summary of Use during Lactation

Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during lutetium Lu 177 dotatate therapy and for 2.5 months following the last dose, which would usually mean permanently discontinuing breastfeeding of the current infant.

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[1]

Drug Levels

Lutetium 177 decays to stable hafnium (Hf 177) with a half-life of 6.65 days, by emitting beta radiation with a maximum energy of 0.498 MeV and photonic gamma radiation of 0.208 MeV and 0.113 MeV.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863–73. PubMed PMID: 10809203.

Substance Identification

Substance Name

Lutetium Lu 177 Dotatate

CAS Registry Number

437608-50-9

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Lutetium Radioisotopes